Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Diagnostics › Molecular Diagnostics › VA to Conduct Large Randomized Trial to Study Impact of Myriad GeneSight Test in Depression

VA to Conduct Large Randomized Trial to Study Impact of Myriad GeneSight Test in Depression

Nov 10, 2017
|
staff reporter

NEW YORK (GenomeWeb) – The US Department of Veterans Affairs has launched a large, randomized clinical trial to assess whether using Myriad Genetics' GeneSight pharmacogenetic test helps get patients with major depressive disorder to the right treatment and improves their outcomes.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

What's Popular?

In Molecular Diagnostics

  1. Infectious Disease Test Firm Talis Biomedical Files for IPO

  2. NASA Looking to Spin Out Breath Analysis Platform for Use in Diagnostics Applications

    Premium

  3. Fluxergy Aiming to Provide Low-Cost, Multimodal Testing for SARS-CoV-2, Other Disease Targets

    Premium

  4. President Biden Announces Plan to Expand SARS-CoV-2 Testing, Increase Capacity

  5. NeoGenomics to Grow Pharma, Informatics Divisions Through CDx Agreements, Acquisitions

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.